

SPRAVATO® REMS



Outpatient Healthcare Setting Enrollment Form

INSTRUCTIONS:

- 1. Review the SPRAVATO® Prescribing Information and the SPRAVATO® REMS Program Overview
- 2. Complete this form online at www.SPRAVATOrems.com.

This form is intended only for Outpatient Medical Offices and Clinics. Emergency departments within hospitals are certified through the Inpatient Healthcare Setting enrollment.

* Indicates Required Field							
Healthcare Setting Information							
Healthcare Setting Name*:							
Healthcare Setting Address 1*:			Address L	Address Line 2:			
City*:			State*:			ZIP*:	
Healthcare Setting Telephone Number*:			Healthcar	Healthcare Setting Website URL:			
DEA License Number* (associated with the Healthcare Setting	address):	Name of DEA Licens	e Holder (if o	ifferent from Healthcare Settin	ng Name):	DEA License Expiration Date (MM/DD/YYYY)*:	
Healthcare Setting Type* (select all that apply) Mental Health Facility Outpatient Clinic Independent Practice Group Practice Hospital Outpatient Department (HOPD) Other:							
If your healthcare setting is an inc	depend	dent (private)	practi	ce, group prac	ctice,	outpatient clinic, or	
HOPD, how does your practice inte	end to a	acquire SPRA	/ATO®	for patients? (Se	elect a	II that apply)	
☐ By sending a patient-specific p	rescrip	tion for SPRA	VATO	CIII (controlle	d subs	stance) to a REMS-	
certified pharmacy, have that pharmacy deliver patient-name product to your practice, and follow all							
required State and Federal DE	A laws	and regulatio	าร.				
☐ By acquiring SPRAVATO® CIII	(contr	olled substan	ce) as b	ulk supply dire	ctly fro	om a SPRAVATO® REMS-	
qualified distributor, and follow	•		•		•		
For each additional healthcare se	tting w	here SPRAVA	TO® w	ill be delivered,	, dispe	ensed, and administered	
within your healthcare system for which the same Authorized Representative will be responsible, you will need to complete page 3.							
	ط النبيد ص	o oborod with	lanaa	n'a nationt aun	on ort	and distribution northers to	
Your healthcare setting informatio			Jansse	en s pallent sup	pport a	and distribution partners to	
allow your healthcare setting to purchase product.							
Your healthcare setting information (name, location, and phone number) will be listed on a location finder as a certified healthcare setting, available to healthcare professionals and patients seeking treatment with							
SPRAVATO®. If you do not want your information listed, please call SPRAVATO® REMS at							
1-855-382-6022.							
Healthcare Setting Authorized Representative Information							
First Name*:		MI		Last Name*:			
Credentials*: ☐ Physician ☐ Physician Assistant ☐ Nurse ☐ Pharmacist ☐ Nurse Practitioner ☐ Other:							
Telephone Number*:	EXT:	Fax*:			Email Ad	dress*:	
Healthcare Setting Alternate Contact							
First Name:			Last Nam	9:			
Telephone Number:	EXT:	Fax:	1		Email Add	dress:	

Healthcare providers should report suspected adverse events or product quality complaints associated with SPRAVATO® to Janssen at 1-800-JANSSEN (1-800-526-7736) or the FDA at 1-800-FDA-1088 or online at www.fda.gov/medwatch.

Phone: 1-855-382-6022



SPRAVATO® REMS



Outpatient Healthcare Setting Enrollment Form

Healthcare Setting Authorized Representative Agreement

I am the Authorized Representative designated by my healthcare setting to carry out the certification process and oversee implementation and coordinate the activities of the SPRAVATO® REMS. By signing this form, I agree, on behalf of the healthcare setting, to comply with all REMS requirements:

To become certified to dispense, I will:

- Have a prescriber onsite during SPRAVATO® administration and monitoring.
- Have healthcare provider(s) and a pulse oximeter to monitor patients onsite.
- Review the SPRAVATO[®] Prescribing Information and REMS Program Overview.
- Enroll in the SPRAVATO® REMS by completing and submitting the Outpatient Healthcare Setting Enrollment Form.
- Establish processes and procedures to:
 - o Enroll the patient in the SPRAVATO® REMS.
 - Counsel the patient on the requirement for enrollment, monitoring, and the risks of sedation, dissociation, respiratory depression and other changes in vital signs, and the need to have arrangements to safely leave the healthcare setting and not engage in potentially hazardous activities.
 - Verify the patient is enrolled in the REMS before each administration.
 - Verify SPRAVATO[®] is not dispensed for use outside the certified healthcare setting.
 - o Complete and submit the Patient Monitoring Form after each administration within 7 calendar days.
 - o Identify all staff involved in prescribing, dispensing, and administering SPRAVATO® and ensure they are trained on:
 - Counseling the patient on the requirement for monitoring and risks of sedation, dissociation, respiratory depression, and other changes in vital signs, and the need to have arrangements to safely leave the healthcare setting and not engage in hazardous activities.
 - Patient administration under the supervision of a healthcare provider.
 - Monitoring for resolution of sedation, dissociation, respiratory depression using pulse oximetry and other changes in vital signs for a minimum of 2 hours.

Before treatment initiation, I will:

- Counsel the patient on the requirement for monitoring for resolution of sedation, dissociation, respiratory depression, and
 other changes in vital signs, and on the need to have arrangements to safely leave the healthcare setting and not engage
 in potentially hazardous activities.
- Enroll the patient by completing and submitting the Patient Enrollment Form to the REMS.

Before administering, I will:

- Counsel the patient on the requirement for monitoring for resolution of sedation, dissociation, respiratory depression, and other changes in vital signs, and the need to have arrangements to safely leave the healthcare setting and not engage in potentially hazardous activities.
- Verify the patient is enrolled in the REMS through the processes and procedures established as a requirement of the REMS.

During and after administering, for at least 2 hours, I will:

• Assess the patient for administration of SPRAVATO® and resolution of sedation, dissociation, respiratory depression using pulse oximetry, and other changes in vital signs.

After administering, within 7 calendar days, I will:

• Document and submit to the REMS using the Patient Monitoring Form.

To maintain certification to dispense, I will:

 Have any new authorized representative enroll in the REMS by completing the Outpatient Healthcare Setting Enrollment Form.

At all times, I will:

- Not dispense SPRAVATO® for use outside a certified healthcare setting.
- Not distribute, transfer, loan, or sell SPRAVATO[®].
- Maintain records documenting staff's completion of training.
- Maintain records that all processes and procedures are in place and are being followed.
- Maintain records of all shipments of SPRAVATO[®] received and dispensing information including patient name, dose, number of devices, and date administered.
- Comply with audits carried out by Janssen Pharmaceuticals, Inc., or a third party acting on behalf of Janssen Pharmaceuticals, Inc., to ensure that all processes and procedures are in place and are being followed.

Name (olease	print):
---------------------	--------	---------

Phone: 1-855-382-6022

Healthcare providers should report suspected adverse events or product quality complaints associated with SPRAVATO® to Janssen at 1-800-JANSSEN (1-800-526-7736) or the FDA at 1-800-FDA-1088 or online at www.fda.gov/medwatch.



SPRAVATO® REMS



Fax: 1-877-778-0091

Outpatient Healthcare Setting Enrollment Form

Use this page to add each additional healthcare setting location for which the <u>same</u>
Authorized Representative will be responsible.

* Indicates Required Field

Additional Healthcare Setting							
Authorized Representative First Name*:			MI:	Last Name*:			
Authorized Representative E	mail:						
Healthcare Setting Name *:	Healthcare Setting Name *:						
Healthcare Setting Address 1*:				Address Line 2:			
City*: State*:				ZIF)*.		
Healthcare Setting Telephone Number*:				Healthcare Setting Website URL:			
DEA License Number* (associated with the Healthcare Setting address):		ss): Name of D	Name of DEA License Holder (if different from Healthcare Setting Name): DEA License		ne): DEA License Expiration Date (MM/DD/YYYY)*:		
Healthcare Setting Type* (select all that apply)	☐ Mental Health Fac		·				
If your healthcare setting is an independent (private) practice, group practice, outpatient clinic, or HOPD, how does your practice intend to acquire SPRAVATO [®] for patients? (Select all that apply) By sending a patient-specific prescription for SPRAVATO [®] CIII (controlled substance) to a REMS-certified pharmacy, have that pharmacy deliver patient-name product to your practice, and follow all required State and Federal DEA laws and regulations. By acquiring SPRAVATO [®] CIII (controlled substance) as bulk supply directly from a SPRAVATO [®] REMS-qualified distributor, and follow all required State and Federal DEA laws and regulations.							
Additional Alterna	ate Contact Informat	tion					
First Name:				Last Name:			
Telephone Number:		EXT:	Fax:		Email Address:		
Your healthcare setting information will be shared with Janssen's patient support and distribution partners, to allow your outpatient healthcare setting to purchase product.							
a certified healtho	care setting, availab	ole to health	ncare p	nd phone number) will be rofessionals and patients isted, please call SPRA	_		
1-855-382-6022.				· •			

Healthcare providers should report suspected adverse events or product quality complaints associated with SPRAVATO® to Janssen at 1-800-JANSSEN (1-800-526-7736) or the FDA at 1-800-FDA-1088 or online at www.fda.gov/medwatch.

Phone: 1-855-382-6022